Scotiabank Maintains Sector Outperform on Arcturus Therapeutics, Raises Price Target to $35

Benzinga · 07/02 14:24
Scotiabank analyst Greg Harrison maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Sector Outperform and raises the price target from $32 to $35.